In this video, Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights a Phase I study investigating the use of the anti-ROR1 antibody-conjugate zilovertamab vedotin in the treatment of mantle cell lymphoma (MCL). Dr Wang briefly explains the mechanism of action of zilovertamab vedotin, and the high response rates that have been observed in patients so far. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.